fr   en

Browse by date
Or search by keyword
Date: 2010-09-02
Biotech partner: Morphosys (Germany) Absynth (UK)
Type of agreement: * R&D
* licensing
* other
Compound: novel infectious disease targets
Disease area: Staphylococcus aureus infections including MRSA (methicillin-resistant S. aureus).
Nature of the agreement: MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics, providing access to novel target molecules associated with Staphylococcus aureus infections including MRSA (methicillin-resistant S. aureus). MorphoSys will generate antibodies using its proprietary HuCAL PLATINUM antibody library which Absynth will test in relevant disease models. MorphoSys will be solely responsible for the development and partnering of the resulting compounds.
Financial terms of the agreement: Absynth will receive an upfront payment and is eligible for development-dependent milestone payments and royalties. Further financial details were not disclosed.

Go back to previous page